Hydrocorrhizone does not reduce BPD, but has benefits on secondary outcomes

This meta-analysis of seven trials involving over 2,000 neonates found that hydrocorrhizone did not reduce bronchopulmonary dysplasia (BPD). However, the analysis revealed several secondary outcomes in which hydrocorrhizone showed benefits. It significantly reduced mortality and necrotizing enterocolitis (NEC). The effectiveness of hydrocorrhizone in reducing BPD was inversely associated with the duration of treatment, with a 10 to 12-day duration yielding better results. Neonates with chorioamnionitis showed greater response to hydrocorrhizone. These findings suggest that hydrocorrhizone could be considered on a case-by-case basis for certain secondary outcomes.